A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women
living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of
preventing malaria and other common perinatal infections would have great potential to
improve adverse birth outcomes. The purpose of this randomized controlled trial is to
evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to
determine its efficacy and safety.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
Azithromycin Trimethoprim, Sulfamethoxazole Drug Combination